PMID- 26800365
OWN - NLM
STAT- MEDLINE
DCOM- 20160825
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 17
IP  - 6
DP  - 2016
TI  - Developing drugs for use before, during and soon after percutaneous coronary 
      intervention.
PG  - 803-18
LID - 10.1517/14656566.2016.1145666 [doi]
AB  - INTRODUCTION: Percutaneous coronary intervention (PCI) is a milestone for 
      treating coronary artery disease (CAD). Antithrombotic therapy is essential to 
      prevent ischemic complications, including the microvascular no-reflow, while 
      minimizing bleeding events. AREAS COVERED: This overview discusses available and 
      developing drugs for PCI including anticoagulants, antiplatelets and treatment of 
      no-reflow. EXPERT OPINION: For years unfractionated heparin (UFH) has been the 
      unique anticoagulant to be used before and during PCI. Enoxaparin showed similar 
      efficacy and safety, yet, based on recent trials, bivalirudin has been shown to 
      have some benefits, particularly for patients with ST-segment elevation 
      myocardial infarction (STEMI). The evidence concerning new anticoagulants is 
      still preliminary, except for new oral anticoagulants, particularly rivaroxaban 
      that showed intriguing findings and is currently under investigation. Dual 
      antiplatelet therapy (DAPT) is the standard of care after PCI, but new 
      developments have recently emerged. Indeed, ticagrelor and prasugrel are 
      currently recommended over clopidogrel due to their significant reduction of 
      ischemic events in acute coronary syndrome (ACS) whereas clopidogrel remains the 
      choice in stable CAD. Among new agents, vorapaxar and cangrelor showed positive 
      but limited evidence and might be considered at least in selected patients. 
      Conversely, evidence on effective treatments for no-reflow remains limited and 
      would require future dedicated research.
FAU - Gargiulo, Giuseppe
AU  - Gargiulo G
AD  - a Department of Cardiology , Bern University Hospital , Bern , Switzerland.
AD  - b Department of Advanced Biomedical Sciences , Federico II University of Naples , 
      Naples , Italy.
FAU - Moschovitis, Aris
AU  - Moschovitis A
AD  - a Department of Cardiology , Bern University Hospital , Bern , Switzerland.
FAU - Windecker, Stephan
AU  - Windecker S
AD  - a Department of Cardiology , Bern University Hospital , Bern , Switzerland.
FAU - Valgimigli, Marco
AU  - Valgimigli M
AD  - a Department of Cardiology , Bern University Hospital , Bern , Switzerland.
AD  - c Thoraxcenter , Erasmus Medical Center , Rotterdam , The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160303
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Artery Disease/*drug therapy/therapy
MH  - Hemorrhage/chemically induced
MH  - Heparin/therapeutic use
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - Drugs
OT  - anticoagulant
OT  - antiplatelet
OT  - no-reflow
OT  - percutaneous coronary intervention
EDAT- 2016/01/23 06:00
MHDA- 2016/08/26 06:00
CRDT- 2016/01/23 06:00
PHST- 2016/01/23 06:00 [entrez]
PHST- 2016/01/23 06:00 [pubmed]
PHST- 2016/08/26 06:00 [medline]
AID - 10.1517/14656566.2016.1145666 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2016;17(6):803-18. doi: 10.1517/14656566.2016.1145666. 
      Epub 2016 Mar 3.